HD-OPM Archive
Topics › Aspirin, antiplatelets & blood thinners

2026 ACC statement: daily aspirin for primary prevention adds bleeding with little benefit

Louis Nervegna · Jul 18, 2026 · ♥ 8 reactions · 5 comments · original Facebook post
Aspirin, antiplatelets & blood thinnersGuidelines, policy & public health
AI summary & key facts

A quoted summary of the 2026 ACC antiplatelet statement says pooling 13 trials of 165,265 people, aspirin modestly reduced heart attacks and strokes but raised major bleeding and did not reduce all-cause death. Benefit faded in trials after 2000, likely because statins now supply the protection.

Quoted:

If you take a daily aspirin for your heart — and you’ve never had a heart attack, stent, or stroke — the guidance has just shifted.

The American College of Cardiology’s 2026 scientific statement on antiplatelet therapy has updated the position on aspirin for primary prevention: taking it to prevent a first cardiac event.

When 13 trials covering 165,265 people were pooled, daily aspirin modestly reduced heart attacks and strokes (hazard ratio 0.89) but increased major bleeding (hazard ratio 1.43). It did not reduce death from any cause. Across the analysis, roughly 1 in 241 people benefited, while serious bleeding into the brain occurred in about 1 in 880.

The most telling detail: aspirin’s benefit was clear in trials begun before 2000 and faded in trials since. The likely explanation is that modern statin therapy now delivers the protection aspirin once added — without the bleeding cost. Save this and share it with someone who takes a daily aspirin.

Reference: Kumbhani DJ, Gibson CM, Kinlay S, et al. Antiplatelet therapy in the management of atherosclerotic cardiovascular disease: 2026 ACC scientific statement. J Am Coll Cardiol. 2026. doi:10.1016/j.jacc.2026.05.037

#aspirinHD #accHD #guidelinesHD #bleedingHD

Research cited

← newer: Whey protein raised IGF-1 but not muscle or strength in 24-wolder: Somatic mutations may set an upper bound on human lifespan →